Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tyruko® (natalizumab-sztn) – New first-time biosimilar approval
August 24, 2023 - The FDA announced the approval of Polypharma Biologics and Sandoz’s Tyruko (natalizumab-sztn), biosimilar to Biogen’s Tysabri® (natalizumab).
